Cover Image
市場調查報告書

肝素的歐洲市場 - 2016∼2024年:各產品、各最終用途產業分析、規模、佔有率、成長、趨勢及預測

Heparin Market (Product - Low Molecular Weight Heparin, Unfractionated Heparin, Ultra-low Molecular Weight Heparin; End Applications - Hospitals, Blood and Stem Cell Bank) - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

出版商 Transparency Market Research 商品編碼 335188
出版日期 內容資訊 英文 101 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
肝素的歐洲市場 - 2016∼2024年:各產品、各最終用途產業分析、規模、佔有率、成長、趨勢及預測 Heparin Market (Product - Low Molecular Weight Heparin, Unfractionated Heparin, Ultra-low Molecular Weight Heparin; End Applications - Hospitals, Blood and Stem Cell Bank) - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024
出版日期: 2016年08月29日 內容資訊: 英文 101 Pages
簡介

本報告提供歐洲的肝素市場相關詳細分析,2016∼2024年的成長預測,各產品,各國趨勢,及參與企業簡介彙整。

第1章 序

第2章 調查的前提條件及調查方法

第3章 摘要整理

第4章 市場概要

  • 產品概要
  • 主要的產業內的事件
  • 歐洲的腦血管障礙(CVD)的死亡率(2015年)
  • EU主要的死因
  • 醫藥品支出(2013年及2014年)

第5章 市場動態

  • 推動市場因素和阻礙因素的簡易分析
  • 推動市場的要素
    • 歐洲的凝固及腎臟疾病的發病率的上升
    • 肉類處理業者打算進入肝素粗品加工業務,預計可解除歐洲的供需缺口
    • 禁止由中國進口促進歐洲的生產
    • 安全且成本效率佳的肝素產品的商品化
  • 阻礙市場的要素
    • 抗凝固劑替代產品的穩定供給阻礙生物學性肝素產品的銷售額
    • 品管對策和環境支援的強化提高肝素生產的成本
    • 發明專利權的失效和仿單標示外產品的使用增加
    • 肝素誘發血小板減少症的風險
  • 市場機會
    • 生物製品的替代品的生技仿製藥
    • 海洋肝素產品相關的替代品研究
  • 機會分析
  • 價格詳細及市場預測

第6章 各產品市場

  • 主要調查結果
  • 市場價格佔有率分析
  • 市場規模預測
    • 低分子量肝素
    • 未分級肝素
    • 超低分子量肝素
  • 主要趨勢
  • 市場魅力度分析

第7章 各終端用戶市場

  • 主要調查結果
  • 簡介
  • 市場價格佔有率分析
  • 市場規模預測
    • 醫院
    • 血液/幹細胞銀行
    • 其他
  • 主要趨勢

第8章 各國市場

  • 市場價格的佔有率分析
  • 德國
  • 銑刀
  • 英國
  • 義大利
  • 西班牙
  • 波蘭
  • 瑞士
  • 奧地利
  • 匈牙利
  • 比利時
  • 葡萄牙
  • 捷克
  • 希臘
  • 斯洛伐克
  • 歐洲的其他國
  • 市場魅力度分析

第9章 競爭情形

  • 各企業歐洲市場佔有率
  • 競爭矩陣
    • Sanofi SA
    • GlaxoSmithKline plc
    • Pfizer, Inc.
    • Leo Pharma
    • Dr. Reddy's Laboratories
    • Fresenius SE & Co. KG
    • Teva Pharmaceutical Industries Ltd.

第10章 企業簡介

  • Sanofi SA
  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Leo Pharma
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius SE & Co. KG
  • Teva Pharmaceutical Industries Ltd.

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

This report provides in-depth country wise analysis of the heparin market in Europe. Stakeholders of this report include manufacturers of heparin products, crude heparin suppliers, heparin processing companies, and new players planning to enter the market.

The report provides qualitative and quantitative analysis of the heparin market in Europe. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market information. Quantitative analysis includes market share held by companies in 2015, market size, and forecast for the heparin market in major countries in Europe such as Germany, France, the U.K., Italy, Spain, Poland, Switzerland, Austria, Hungary, Belgium, Portugal, the Czech Republic, Greece, Slovakia, and Rest of Europe from 2014 to 2024. Market revenue is provided in terms of US$ Mn from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 for all the segments, considering 2015 as the base year. The executive summary of the report provides a snapshot of the heparin market in Europe with information on leading segments, country wise market information with respect to the market size, growth rate (CAGR %), and growth factors.

The market overview section comprises impact factors such as drivers, restraints, and opportunities for the heparin market in Europe. These factors would aid the stakeholders in establishing a strong foothold in Europe. Furthermore, the market overview section comprises key industry events, product overview, mortality rate of CVD in Europe, leading causes of death, and country-wise pharmaceutical expenditure. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments to identify the most attractive market.

Market share analysis is also provided in the competitive landscape section of the report for the year 2015 in terms of value (%). Furthermore, the report analyzes different heparin product types such as unfractionated heparin, low molecular weight heparin, and ultra-low molecular weight heparin. The product type section provides market analysis for different types of heparin in Europe. This includes an overview of product types, indications for use, presence of any biosimilars, market drivers, issues, and regulations amended for its production and use. Prices of products vary based on product type and formulation. Moreover, the heparin market by end-users such as hospitals, blood and stem cell banks, and others has also been analyzed in the report. The report provides average pricing analysis (based on the current prices) to offer an overview of prices of heparin-based pharmaceutical products in the EU (2015 & 2024).

The report provides market analysis for heparin in the major countries in the EU: Germany, France, the U.K., Italy, Spain, Poland, Switzerland, Austria, Hungary, Belgium, Portugal, the Czech Republic, Greece, Slovakia, and Rest of Europe. Market analysis for each of these countries has been provided from 2014 to 2024 along with the CAGR from 2016 to 2024. The market has been estimated for finished heparin formulation and has not considered its APIs. Major factors such as aging population and increasing prevalence of venous thromboembolism (VTE) that propel the market for heparin in Europe are elaborated in the report. This report also covers certain regulations governing the manufacture and import of heparin in some countries.

Major players operating in the heparin market in Europe such as Dr. Reddy's Laboratories Ltd., Leo Pharma, Pfizer, Inc., Sanofi SA, and Teva Pharmaceutical Industries Ltd. are profiled in this report.

The Europe heparin market is segmented into the following categories:

Europe Heparin Market, by Product

  • Unfractionated Heparin
  • Low Molecular Weight Heparin
  • Ultra-low Molecular Weight Heparin

Europe Heparin Market, by End-user

  • Hospitals
  • Blood and Stem Cell Banks
  • Others

Europe Heparin Market, by Country

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Poland
  • Switzerland
  • Austria
  • Hungary
  • Belgium
  • Portugal
  • Czech Republic
  • Greece
  • Slovakia
  • Rest of Europe

Table of Contents

1. Preface

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Objectives
  • 1.4. Key Questions Answered

2. Assumptions and Research Methodology

  • 2.1. Report Assumptions
  • 2.2. Acronyms Used
  • 2.3. Research Methodology

3. Executive Summary

  • 3.1. Europe Heparin Market Snapshot
  • 3.2. Key Trends

4. Market Overview

  • 4.1. Product Overview
  • 4.2. Key Industry Events
  • 4.3. Death Rate of CVD in Europe, 2015
  • 4.4. Top Causes of Death in the EU
  • 4.5. Pharmaceutical Expenditure, 2014
  • 4.6. Pharmaceutical Expenditure, 2013

5. Market Dynamics

  • 5.1. Drivers and Restraints Snapshot Analysis
  • 5.2. Drivers
    • 5.2.1. Rise in incidence of coagulation and renal disorders in Europe
    • 5.2.2. Inclination of slaughterhouse owners to enter crude heparin processing business expected to overcome demand-supply gap
    • 5.2.3. Ban on imports from China to boost production in Europe
    • 5.2.4. Commercialization of safe and cost-effective heparin products
  • 5.3. Restraints
    • 5.3.1. Availability of alternative anticoagulants impeding sale of biological heparin products
    • 5.3.2. Enhanced quality control measures and environmental factors elevating the cost of heparin production
    • 5.3.3. Patent loss and increasing use of off-label products
    • 5.3.4. Risk of heparin induced thrombocytopenia
  • 5.4. Opportunities
    • 5.4.1. Biosimilars as an alternative to biological-based products
    • 5.4.2. Research activities on marine-based heparin products
  • 5.5. Opportunity Analysis
  • 5.6. Pricing and Market Projections

6. Europe Heparin Market Analysis, by Product Type

  • 6.1. Key Findings
  • 6.2. Market Value Share Analysis, by Product Type, 2015 and 2024
  • 6.3. Europe Heparin Market Size (US$ Mn) Forecast, by Product, 2014-2024
    • 6.3.1. Low Molecular Weight Heparin
    • 6.3.2. Unfractionated Heparin
    • 6.3.3. Ultra-low Molecular Weight Heparin
  • 6.4. Key Trends
  • 6.5. Market Attractiveness Analysis, by Product, 2015

7. Europe Heparin Market Analysis, by End-user

  • 7.1. Key Findings
  • 7.2. Introduction
  • 7.3. Market Value Share Analysis, by End-user, 2015 and 2024
  • 7.4. Europe Heparin Market Size (US$ Mn) Forecast, by End-user, 2014-2024
    • 7.4.1. Hospitals
    • 7.4.2. Blood and Stem Cell Bank
    • 7.4.3. Others
  • 7.5. Key Trends

8. Europe Heparin Market Analysis, by Country

  • 8.1. Market Value Share Analysis, by Country, 2015 and 2024
  • 8.2. Germany
  • 8.3. France
  • 8.4. U.K.
  • 8.5. Italy
  • 8.6. Spain
  • 8.7. Poland
  • 8.8. Switzerland
  • 8.9. Austria
  • 8.10. Hungary
  • 8.11. Belgium
  • 8.12. Portugal
  • 8.13. Czech Republic
  • 8.14. Greece
  • 8.15. Slovakia
  • 8.16. Rest of Europe
  • 8.17. Market Attractiveness Analysis, by End-user, 2015

9. Competitive Landscape

  • 9.1. Europe Heparin Market Share Analysis, by Company (2015)
  • 9.2. Competition Matrix
    • 9.2.1. Sanofi SA
    • 9.2.2. GlaxoSmithKline plc
    • 9.2.3. Pfizer, Inc.
    • 9.2.4. Leo Pharma
    • 9.2.5. Dr. Reddy's Laboratories
    • 9.2.6. Fresenius SE & Co. KG
    • 9.2.7. Teva Pharmaceutical Industries Ltd.

10. Company Profiles

  • 10.1. Sanofi SA
    • 10.1.1. Company Details
    • 10.1.2. Company Description
    • 10.1.3. Business Overview
    • 10.1.4. SWOT Analysis
    • 10.1.5. Financial Analysis
    • 10.1.6. Strategic Overview
  • 10.2. GlaxoSmithKline plc
    • 10.2.1. Company Details
    • 10.2.2. Company Description
    • 10.2.3. Business Overview
    • 10.2.4. SWOT Analysis
    • 10.2.5. Financial Analysis
    • 10.2.6. Strategic Overview
  • 10.3. Pfizer, Inc.
    • 10.3.1. Company Details
    • 10.3.2. Company Description
    • 10.3.3. Business Overview
    • 10.3.4. SWOT Analysis
    • 10.3.5. Financial Analysis
    • 10.3.6. Strategic Overview
  • 10.4. Leo Pharma
    • 10.4.1. Company Details
    • 10.4.2. Company Description
    • 10.4.3. Business Overview
    • 10.4.4. SWOT Analysis
    • 10.4.5. Financial Analysis
    • 10.4.6. Strategic Overview
  • 10.5. Dr. Reddy's Laboratories
    • 10.5.1. Company Details
    • 10.5.2. Company Description
    • 10.5.3. Business Overview
    • 10.5.4. SWOT Analysis
    • 10.5.5. Financial Analysis
    • 10.5.6. Strategic Overview
  • 10.6. Fresenius SE & Co. KG
    • 10.6.1. Company Details
    • 10.6.2. Company Description
    • 10.6.3. Business Overview
    • 10.6.4. SWOT Analysis
    • 10.6.5. Financial Analysis
    • 10.6.6. Strategic Overview
  • 10.7. Teva Pharmaceutical Industries Ltd.
    • 10.7.1. Company Details
    • 10.7.2. Company Description
    • 10.7.3. Business Overview
    • 10.7.4. SWOT Analysis
    • 10.7.5. Financial Analysis
    • 10.7.6. Strategic Overview

List of Figures

  • FIG. 1: Europe Heparin Market Revenue (US$ Mn), 2015
  • FIG. 2: Europe Heparin Market Size (US$ Mn) Forecast, 2014-2024
  • FIG. 3: Europe Heparin Average Pricing Analysis (US$) 2015-2024
  • FIG. 4: Europe Heparin Market Value Share Analysis By Product, 2016 and 2024
  • FIG. 5: Europe LMWH Market Revenue, (US$ Mn), 2014-2024
  • FIG. 6: Europe Unfractionated Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 7: Europe ULMWH Market Revenue, (US$ Mn), 2014-2024
  • FIG. 8: Europe Heparin Market Value Share Analysis By End-user, 2016 and 2024
  • FIG. 9: Europe Hospitals Heparin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 10: Europe Blood and Stem Cell Bank Heparin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 11: Europe Others (End-user) Heparin Market Revenue, (US$ Mn), 2014-2024
  • FIG. 12: Europe Heparin Market Value Share Analysis, by Country, 2015 and 2024
  • FIG. 13: Germany Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 14: France Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 15: UK Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 16: Italy Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 17: Spain Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 18: Poland Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 19: Switzerland Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 20: Austria Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 21: Hungary Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 22: Belgium Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 23: Portugal Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 24: Czech Republic Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 25: Greece Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 26: Slovakia Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 27: Rest of Europe Heparin Market Revenue (US$ Mn), 2014-2024
  • FIG. 28: Heparin Market Attractiveness Analysis, by Product, 2015
  • FIG. 29: Heparin Market Attractiveness Analysis, by End-user, 2015
  • FIG. 30: Europe Heparin Market Share Analysis By Company (2015)

List of Tables

  • TABLE 1: Europe Heparin Market Size (US$ Mn) Forecast, By Product, 2016-2024
  • TABLE 2: Europe Heparin Market Size (US$ Mn) Forecast, By End-user, 2016-2024
  • TABLE 3: Europe Heparin Market Size (US$ Mn) Forecast, by Country, 2014-2024
Back to Top